Work

Adjuvant Abemaciclib Plus Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A

Year: 2022

Type: article

Abstract: Question: How Should We Be Using Ki-67 When Considering Abemaciclib?At this time, the Ki-67 selection required by the FDA approval excludes a cohort of patients expected to

Source: JCO Oncology Practice

DOI: 10.1200/op.22.00140

Authors: Rachel A. Freedman, Stephanie L. Graff, Mark R. Somerfield, Melinda L. Telli, Antonio C. Wolff, Sharon H. Giordano

Institutions: Dana-Farber Cancer Institute, Lifespan, American Society of Clinical Oncology, Stanford Medicine, Stanford University, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, The University of Texas MD Anderson Cancer Center

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funder: American Society of Clinical Oncology

OpenAlex ID: W4225822825

FWCI: 1.773

Cites: 10

Cited by: 12

Related to: 10